What to Look for Before Buying a Pharma Stock
Key Points
When researching pharma companies, investors might start by reviewing the drug pipeline.
Companies constantly need to be developing their next flagship drug.
Pfizer shows why a strong pipeline is so important.
- 10 stocks we like better than Pfizer ›
There are many criteria for evaluating a pharmaceutical stock, but one of the easiest to start with is the drug pipeline. You can do so by looking at quarterly reports or listening to earnings calls, as companies tend to spotlight their most promising developments. It's a worthwhile exercise, as a strong pipeline can be the difference between a pharmaceutical company being a leader or a laggard, shaping the future of your investment.
Today, using Pfizer (NYSE: PFE) as an example, we'll see why it's so important to always have a potential flagship drug lined up.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
Staying ready for what's next
When Pfizer launched its COVID-19 vaccine, it was a game-changer for the company. Revenue nearly doubled from $41.6 billion in 2020 to $81.2 billion in 2021. It climbed even further in 2022, reaching roughly $100 billion.
As demand for the vaccine peaked, the story was different in 2023, with sales slumping to around $58 billion. Granted, revenue has still been higher over the past few years than it was before COVID-19, but the stock price is also down about 29% over the last five years as demand for Pfizer's vaccine dropped.
In an attempt to find its next hit, Pfizer acquired Metsera, which doesn't have any drugs on the market now but has weight-loss drug candidates in trials. Pfizer also acquired Seagen in 2023 to bolster its oncology business.
Through Pfizer, we've seen a case study for why having that strong pipeline is so critical. If companies are caught flatfooted when patents expire or drug demand wanes, shareholders may pay the price.
Should you buy stock in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $573,160!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,204,712!*
Now, it’s worth noting Stock Advisor’s total average return is 1,002% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 15, 2026.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.
Recommended Articles
